Yes, patients with a prior episode of bacterial vaginosis are at increased risk for recurrence
Recurrence of BV is not unusual, and women who have had one episode should be counseled that symptoms may return 1. The evidence consistently demonstrates that BV recurrence is common across multiple populations and settings.
Recurrence Rates and Risk
The most recent high-quality research shows that recurrence rates are substantial:
- 53.9% of patients experienced at least one recurrent BV episode during follow-up, with 33.7% experiencing recurrence within just 3 months 2
- The recurrence rate is approximately 22 per 100 person-years 3
- More than 50% of women experience recurrence within 6 months after standard antibiotic treatment 4
- In a recent longitudinal study, 46% of participants had recurrence at 6 months after metronidazole treatment 5
Key Risk Factors for Recurrence
Based on the strongest recent evidence, specific factors increase recurrence risk:
Sexual and Behavioral Factors
- Multiple male partners or female partners in the prior 3 months 3
- Having a regular sexual partner (adjusted recurrence rate ratio 1.32) 3
- Sex work (adjusted recurrence rate ratio 2.02) 3, 2
- Intravaginal practices amplify risk 5
Contraceptive Use
- IUD use increases recurrence risk (hormonal IUD: aHR 1.31; copper IUD: aHR 1.17) 2
- Non-IUD hormonal contraception reduces risk (aHR 0.88) 2
Medical History
- Recent antibiotic use for other conditions significantly increases recurrence 6
- History of sexually transmitted infections 2, 6
- History of Candidiasis 6
Clinical Management Implications
The CDC guidelines explicitly acknowledge this recurrence pattern, stating that "follow-up visits are unnecessary if symptoms resolve. Because recurrence of BV is not unusual, women should be advised to return for additional therapy if symptoms recur" 1.
Important Caveats:
- No long-term maintenance regimen with any therapeutic agent is recommended by current guidelines 1
- Treatment of sex partners does not reduce recurrence according to older guidelines 1, though very recent evidence (2026) suggests partner treatment may help 4
- Another recommended treatment regimen may be used to treat recurrent disease 1
Biological Mechanisms
Recent research reveals that recurrence is driven by:
- Persistent transcriptional activity of Gardnerella and Fannyhessea after treatment 5
- Impaired epithelial integrity (reduced CEACAM5-7 expression) 5
- Persistent inflammation (increased IL-6) 7, 5
- Distinct microbial and inflammatory profiles that persist despite treatment 7
The bottom line: A history of one BV episode is a strong predictor of future episodes, and patients should be counseled accordingly about symptom recognition and when to seek retreatment.